Treatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Compared to Placebo Favorable Safety and Tolerability Observed Conference Call and Webcast to Discuss Data at 8:30 a.m. ET Today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). These data demonstrated that EDP-323 was generally safe and

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will participate in three investor conferences being webcast in September: Baird 2024 Global Healthcare Conference: Fireside Chat at 2:35 p.m. ET on September 10, 2024 H.C. Wainwright 26th Annual Global Investment Conference: Fireside Chat at 10:00 a.m. ET on September 11, 2024 2024 Cantor Global Healthcare Conference: Fireside Chat at 10:55 a.m. ET on September 17, 2024 A live webcast of each event will be accessible by visiting the "Events and Presentations" section on t

Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 Operations Supported by Cash and Marketable Securities Totaling $272.6 Million at June 30, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal third quarter ended June 30, 2024. "We are

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at l

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on May 14, 2024 at 10:00 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at

Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV Patients in 2H 2024 Selection of Chronic Spontaneous Urticaria (CSU) Development Candidate Targeted for Q4 2024 Operations Supported by Cash and Marketable Securities Totaling $300.3 Million at March 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024. "At Enanta, we are commit

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals' Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta's new Chief Legal Officer, consisting of a non-qualified stock option to purchase 150,000 shares of its common stock, performance share units (PSUs) for 4,468 shares of its common stock, and relative total stockholder return units (rTSRUs) for 4,468 shares of its common stock, under the company's 2024 Inducement Stock Incentive Plan. The 20

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's business, including its research and development pipeline. Conference Call and Webcast Information The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta's website. To join by phone, participants can regi

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company's SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain. The poster presentation includes primary and post-hoc analyses from the double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, a 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease. Pos

10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

S-8 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

EFFECT - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

ARS - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology. In this role, Dr. DeVincenzo will provide leadership and direction for Enanta’s pipeline of respiratory antiviral clinical development programs and be responsible for the strategic development and tactical implementation of the clinical studies for these programs. Dr. DeVincenzo brings more than 30 years of clinical research and academic experience to Enanta, predominantly focused

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development. Dr. Kieffer brings over 20 years of virologic research and pharmaceutical industry experience to Enanta, with proven expertise in drug discovery and development, program management and business development, including having played significant roles in developing and launching medicines for infectious and rare diseases. “Tara is joining Enanta at a pivotal time a

Treatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Compared to Placebo Favorable Safety and Tolerability Observed Conference Call and Webcast to Discuss Data at 8:30 a.m. ET Today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). These data demonstrated that EDP-323 was generally safe and

Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 Operations Supported by Cash and Marketable Securities Totaling $272.6 Million at June 30, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal third quarter ended June 30, 2024. "We are

Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV Patients in 2H 2024 Selection of Chronic Spontaneous Urticaria (CSU) Development Candidate Targeted for Q4 2024 Operations Supported by Cash and Marketable Securities Totaling $300.3 Million at March 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024. "At Enanta, we are commit

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's business, including its research and development pipeline. Conference Call and Webcast Information The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta's website. To join by phone, participants can regi

Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024 Expanded into Immunology with New Discovery Program of Oral KIT Inhibitors for First Indication in Chronic Spontaneous Urticaria; Development Candidate Selection Targeted for 2024 Cash and Marketable Securities Totaled $337.2 Million at December 31, 2023 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended December 31, 2023. "In 2024, Enanta began a year which will be marked

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2023 after the U.S. market closes on February 7, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company's business and research and development pipeline. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. To join by phone, participa

Initiated a Phase 2a Challenge Study of EDP-323, an L-Protein Inhibitor, in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Report Data in Q3 2024 Streamlined Business and Significantly Lowered 2024 R&D and G&A Spending Guidance to Support Ongoing Operations Cash and Marketable Securities Totaled $370 Million at September 30, 2023 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023. "Throughout fiscal 2023, Enanta

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2023 after the U.S. market closes on November 20, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company's business and research and development pipeline. Conference Call and Webcast Information A live webcast can be accessed under "Events & Presentations" in the investors section of Enanta's website. To join by phone, participants can register

Reported Positive Topline Data from Phase 1 Study of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. Cash and Marketable Securities Totaled $392.5 Million at June 30, 2023 Royalty Revenue for the Quarter was $18.9 Million Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal third quarter ended June 30, 2023. "Our fiscal third quarter was marked by important progress in our pipeline, most notably across

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2023 after the U.S. market closes on August 7, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company's business and research and development pipeline. Conference Call and Webcast Information The live webcast can be accessed under "Events & Presentations" in the investors section of Enanta's website. To join by phone, participants can register for the call here. I

JP Morgan downgraded Enanta Pharmaceuticals from Neutral to Underweight and set a new price target of $14.00

Jefferies downgraded Enanta Pharmaceuticals from Buy to Hold and set a new price target of $18.00 from $49.00 previously

H.C. Wainwright initiated coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $56.00

Evercore ISI upgraded Enanta Pharmaceuticals from In-line to Outperform and set a new price target of $62.00

Evercore ISI upgraded Enanta Pharmaceuticals from Underperform to In-line and set a new price target of $39.00

SVB Leerink reiterated coverage of Enanta Pharmaceuticals with a rating of Market Perform and set a new price target of $68.00 from $80.00 previously

SVB Leerink reiterated coverage of Enanta Pharmaceuticals with a rating of Market Perform and set a new price target of $80.00 from $85.00 previously

Oppenheimer reiterated coverage of Enanta Pharmaceuticals with a rating of Perform and set a new price target of $73.00 from $55.00 previously

JMP Securities reiterated coverage of Enanta Pharmaceuticals with a rating of Market Outperform and set a new price target of $116.00 from $111.00 previously

SVB Leerink reiterated coverage of Enanta Pharmaceuticals with a rating of Market Perform and set a new price target of $85.00 from $92.00 previously

HC Wainwright & Co. analyst Ed Arce maintains Enanta Pharma (NASDAQ:ENTA) with a Buy and lowers the price target from $28 to $27.

JMP Securities analyst Roy Buchanan maintains Enanta Pharma (NASDAQ:ENTA) with a Market Outperform and lowers the price target from $23 to $22.

Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.47) per share which missed the analyst consensus estimate of $(1.33) by 10.53 percent. This is a 17.88 percent increase over losses of $(1.79) per share from the same period last year. The company reported quarterly sales of $17.054 million which beat the analyst consensus estimate of $16.522 million by 3.22 percent. This is a 4.16 percent decrease over sales of $17.795 million the same period last year.

JP Morgan analyst Eric Joseph maintains Enanta Pharma (NASDAQ:ENTA) with a Underweight and lowers the price target from $12 to $11.

Enanta Pharma (NASDAQ:ENTA) reported its Q1 earnings results on Wednesday, February 7, 2024 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Enanta Pharma missed estimated earnings by 32.77%, reporting an EPS of $-1.58 versus an estimate of $-1.19. Revenue was down $5.58 million from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.67 which was followed by a 11.52% increase in the share price the next day. Here's a look at Enanta Pharma's past performance: Quarter Q4 2023 Q3 2023 Q2 2023 Q1 2023 EPS Estimate -2 -2.33 -1.98 -1.59 EPS Actual -1.33 -1.86 -1.79 -1.39 Revenue Estimate 17.50M 18.06M 19.18M 22

Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(1.58) per share which missed the analyst consensus estimate of $(1.23) by 28.46 percent. This is a 13.67 percent decrease over losses of $(1.39) per share from the same period last year. The company reported quarterly sales of $18.00 million which missed the analyst consensus estimate of $21.95 million by 17.97 percent. This is a 23.67 percent decrease over sales of $23.59 million the same period last year.

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million. • Scotts Miracle Gro (NYSE:SMG) is expected to report quarterly loss at $1.53 per share on revenue of $412.83 million. • TotalEnergies (NYSE:TTE) is projected to report quarterly earnings at $2.28 per share on revenue of $41.80 billion. • Equinor (NYSE:EQNR) is likely to report earnings for its fourth quarter. • Euronet Worldwide (NASDAQ:EEFT) is estimated to report quarterly earnings at $1.76 per share on revenue of $944.71 million. • Flex LNG (NYSE:FLNG) is likely to report quarterly earnings at $0.67 per share on revenue of $9

Enanta Pharma (NASDAQ:ENTA) is set to give its latest quarterly earnings report on Wednesday, 2024-02-07. Here's what investors need to know before the announcement. Analysts estimate that Enanta Pharma will report an earnings per share (EPS) of $-1.19. Enanta Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company beat EPS by $0.67, which was followed by a 11.52% increase

Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); Development Candidate Selection Targeted for 2024 Expect Topline Data from at Least One Phase 2 Study of Zelicapavir (EDP-938), an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV), in 3Q 2024, Pending Continuation of a Normal Northern Hemisphere RSV Season Anticipate Challenge Study Data for EDP-323, an L-Protein Inhibitor in Development to Treat RSV, in 3Q 2024

Oppenheimer analyst Jay Olson maintains Enanta Pharma (NASDAQ:ENTA) with a Perform and lowers the price target from $25 to $21.